Renhe Pharma: First-half Net Profit of 163 Million Year-on-Year, Up 12%

In the first half of 2012, the company achieved operating income of 1,153.7675 million yuan, operating profit of 206.41001 million yuan, net profit of 175,054,800 yuan, and net profit attributable to the parent company's owner of 163,294,100 yuan.

Commercial: Implemented strategic control and strengthened new modes of self-management. All divisions have strengthened the responsibility and enthusiasm of sales personnel at all levels by empowering and clarifying their target responsibilities. This has enabled the effective exploration of the division management model. In response to the changes in the “Toxic Capsule Incident” in the first half of the year and Renhe Youkadan, the company’s product, the company’s commercial staff at all levels actively took the initiative to strengthen the explanation and communication with agents and terminal outlets in an effort to minimize the impact.

Industry: All production companies closely focused on the annual production planning tasks and budget targets, and carried out the theme activities of “reducing costs and increasing efficiency, and improving the basic management level of the workshop”. Through activities, the company will comprehensively increase the level of basic management of workshops in all production companies. It has reached a new height.

New product launch and R&D: The company continued to increase its product development efforts. In the first half of the year, it obtained a new drug production approval document, three drug packaging material approvals, and four hygiene product approvals. 6 approvals were issued to the National Bureau, and 158 were registered by the Provincial Bureau. 4 new products are listed on the market and 5 new products are produced.